MBX BIOSCIENCES INC.

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

28 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 9 2024 16:05:00 提供 Nasdaq GlobeNewswire